NCT06276309 Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
| NCT ID | NCT06276309 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fujian Maternity and Child Health Hospital |
| Condition | Neuroendocrine Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-02-01 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology 2. Clinical data were complete Exclusion Criteria: 1. Patients who are not being treated in our hospital 2. Patients with lack of follow-up data, unable to obtain survival information 3. Patients call to refuse to participate in this project 4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination
Contact & Investigator
Pengming Sun, PhD
STUDY CHAIR
Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT06276309 clinical trial?
This trial is open to female participants only, studying Neuroendocrine Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06276309 currently recruiting?
Yes, NCT06276309 is actively recruiting participants. Contact the research team at dongbinhua86@fjmu.edu.cn for enrollment information.
Where is the NCT06276309 trial being conducted?
This trial is being conducted at Fuzhou, China, Fuzhou, China, Ningde, China, Putian, China and 5 additional locations.
Who is sponsoring the NCT06276309 clinical trial?
NCT06276309 is sponsored by Fujian Maternity and Child Health Hospital. The principal investigator is Pengming Sun, PhD at Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University. The trial plans to enroll 300 participants.